Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Cytokeratin 8 Antibody (AE3) - BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody has been used in 5 publications
Supplier: Novus Biologicals NB1209287
Description
Cytokeratin 8 Monoclonal specifically detects Cytokeratin 8 in Human, Mouse, Rat, Bovine, Chicken, Primate, Rabbit samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen.Specifications
Cytokeratin 8 | |
Monoclonal | |
1.0 mg/mL | |
Western Blot 1:100-1:2000, Flow Cytometry, Immunohistochemistry 1:10-1:500, Immunohistochemistry-Paraffin 1:10-1:500, Immunohistochemistry-Frozen | |
KRT8 | |
Human epidermal cells | |
0.1 mg | |
Primary | |
Recognizes most of the basic (Type II) keratins, HMW cytokeratins. It is broadly reactive and stains positively almost all epithelia and their neoplasms. AE3 reacts with all layers of epidermis (basal layer and above). The antibody is an excellent marker for distinguishing carcinomas from non-epithelial tumours. It has been used for studying the immunolocalisation of epidermal keratins, tissue distribution of keratins, various diseases of epidermis, oral mucosa and other epithelia and other epithelia development. | |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
Western Blot, Flow Cytometry, Immunohistochemistry, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen) | |
AE3 | |
Unconjugated | |
CARD2, CK8, CK-8, CYK8cytokeratin 8, Cytokeratin-8, K2C8, K8cytokeratin-8, keratin 8, keratin, type II cytoskeletal 8, keratin-8, KO, Type-II keratin Kb8 | |
Mouse | |
Affinity Purified | |
RUO | |
3856 | |
Human, Mouse, Rat, Bovine, Chicken, Primate, Rabbit | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction